Summary
Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma.
Similar content being viewed by others
References
Reinhart KL, Gloer JB, Hughes RG, Renis HE, Mcgovrern JP, Swynenberg EB, Stringfellow DA, Kuentzel SL, Li LH: Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 212:933–955, 1981
Dorr FA, Kuhn JG, Phillips J, Von Hoff DD: Phase I clinical and pharmakokinetic investigation of Didemnin B, a cyclic depsipeptide. Eur. J. Cancer Clin. Oncol. 24:1699–1706, 1988
Miller AB, Hoogstrated B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Taylor S, Piston B, Stevens RL, Crawford ED: Phase II Trial of Didemnin B in advanced adenocarcinoma of the kidney: Southwest Oncology Study Group Study. Proc Am Soc Clin Oncol 8:564, 1989 (abstract)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Motzer, R., Scher, H., Bajorin, D. et al. Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. Invest New Drugs 8, 391–392 (1990). https://doi.org/10.1007/BF00198598
Issue Date:
DOI: https://doi.org/10.1007/BF00198598